...
search icon
sage-img

Sage Therapeutic, Common Stock

SAGE

NMQ

$7.79

+$0

(0%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$457.42M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
1.02M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.48
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$4.62 L
$14.71 H
$7.79

About Sage Therapeutic, Common Stock

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. The company offers ZURZUVAE, a neuroactive steroid positive allosteric modulator of GABA receptors targeting synaptic and extrasynaptic GABA receptors for the treatment of postpartum depression in adults. Its product pipeline also includes SAGE-324, a novel GABA receptor positive allosteric modulator for chronic oral dosing, including seizures in developmental and epileptic encephalopathies; and SAGE-319, an extrasynaptic-preferring GABA receptor positive allosteric modulator PAM for treating behavioral symptoms associated with neurodevelopmental disorders. In addition, the company is developing various product candidates, including SAGE-817 and SAGE-039 for the treatment of acute and chronic brain health disorders, including work on allosteric modulation of the GABA and NMDA receptor systems in the brain, as well as NMDA receptor negative allosteric modulator focusing on the treatments for neurodevelopmental disorders. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameSAGESectorS&P500
1-Week Return4.7%3.64%6.36%
1-Month Return-8.68%-5.42%-5.32%
3-Month Return4.7%-6.89%-8.86%
6-Month Return-2.75%-7.54%-5.61%
1-Year Return-42.64%-1.81%8.61%
3-Year Return-76.55%2.1%27.58%
5-Year Return-80.77%35.25%90.38%
10-Year Return-85.73%88.1%160.03%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue1.11B6.31M7.69M86.45M41.24M[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":0.57,"profit":true},{"date":"2022-12-31","value":0.69,"profit":true},{"date":"2023-12-31","value":7.76,"profit":true},{"date":"2024-12-31","value":3.7,"profit":true}]
Cost of Revenue565.00K553.00K813.00K2.16M9.44M[{"date":"2020-12-31","value":5.98,"profit":true},{"date":"2021-12-31","value":5.86,"profit":true},{"date":"2022-12-31","value":8.61,"profit":true},{"date":"2023-12-31","value":22.86,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Gross Profit1.11B5.75M6.87M84.30M31.80M[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":0.52,"profit":true},{"date":"2022-12-31","value":0.62,"profit":true},{"date":"2023-12-31","value":7.57,"profit":true},{"date":"2024-12-31","value":2.86,"profit":true}]
Gross Margin99.95%91.23%89.42%97.50%77.10%[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":91.28,"profit":true},{"date":"2022-12-31","value":89.47,"profit":true},{"date":"2023-12-31","value":97.55,"profit":true},{"date":"2024-12-31","value":77.14,"profit":true}]
Operating Expenses489.67M466.66M553.86M630.76M464.17M[{"date":"2020-12-31","value":77.63,"profit":true},{"date":"2021-12-31","value":73.98,"profit":true},{"date":"2022-12-31","value":87.81,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":73.59,"profit":true}]
Operating Income596.23M(460.91M)(546.99M)(579.85M)(432.37M)[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-77.3,"profit":false},{"date":"2022-12-31","value":-91.74,"profit":false},{"date":"2023-12-31","value":-97.25,"profit":false},{"date":"2024-12-31","value":-72.52,"profit":false}]
Total Non-Operating Income/Expense19.44M5.90M28.39M74.43M63.38M[{"date":"2020-12-31","value":26.12,"profit":true},{"date":"2021-12-31","value":7.93,"profit":true},{"date":"2022-12-31","value":38.15,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":85.15,"profit":true}]
Pre-Tax Income606.07M(457.89M)(532.78M)(541.49M)(400.67M)[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-75.55,"profit":false},{"date":"2022-12-31","value":-87.91,"profit":false},{"date":"2023-12-31","value":-89.34,"profit":false},{"date":"2024-12-31","value":-66.11,"profit":false}]
Income Taxes15.52M(7.07M)(29.52M)(5.36M)(400.67M)[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-45.53,"profit":false},{"date":"2022-12-31","value":-190.24,"profit":false},{"date":"2023-12-31","value":-34.53,"profit":false},{"date":"2024-12-31","value":-2582.28,"profit":false}]
Income After Taxes590.56M(450.83M)(503.27M)(536.13M)-[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-76.34,"profit":false},{"date":"2022-12-31","value":-85.22,"profit":false},{"date":"2023-12-31","value":-90.78,"profit":false},{"date":"2024-12-31","value":"-","profit":true}]
Income From Continuous Operations606.07M(457.89M)(532.78M)(655.93M)(400.67M)[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-75.55,"profit":false},{"date":"2022-12-31","value":-87.91,"profit":false},{"date":"2023-12-31","value":-108.23,"profit":false},{"date":"2024-12-31","value":-66.11,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income606.07M(450.83M)(503.27M)(541.49M)(400.67M)[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-74.38,"profit":false},{"date":"2022-12-31","value":-83.04,"profit":false},{"date":"2023-12-31","value":-89.34,"profit":false},{"date":"2024-12-31","value":-66.11,"profit":false}]
EPS (Diluted)11.64(7.80)(8.98)(10.31)(6.23)[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-67.01,"profit":false},{"date":"2022-12-31","value":-77.15,"profit":false},{"date":"2023-12-31","value":-88.57,"profit":false},{"date":"2024-12-31","value":-53.5,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

SAGE
Cash Ratio 7.04
Current Ratio 7.42

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

SAGE
ROA (LTM) -35.90%
ROE (LTM) -63.37%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

SAGE
Debt Ratio Lower is generally better. Negative is bad. 0.15
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.85

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

SAGE
Trailing PE NM
Forward PE NM
P/S (TTM) 11.61
P/B 1.03
Price/FCF NM
EV/R 0.40
EV/Ebitda NM
PEG 0.74

FAQs

What is Sage Therapeutic share price today?

Sage Therapeutic (SAGE) share price today is $7.79

Can Indians buy Sage Therapeutic shares?

Yes, Indians can buy shares of Sage Therapeutic (SAGE) on Vested. To buy Sage Therapeutic from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in SAGE stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Sage Therapeutic be purchased?

Yes, you can purchase fractional shares of Sage Therapeutic (SAGE) via the Vested app. You can start investing in Sage Therapeutic (SAGE) with a minimum investment of $1.

How to invest in Sage Therapeutic shares from India?

You can invest in shares of Sage Therapeutic (SAGE) via Vested in three simple steps:

  • Click on Sign Up or Invest in SAGE stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Sage Therapeutic shares
What is Sage Therapeutic 52-week high and low stock price?

The 52-week high price of Sage Therapeutic (SAGE) is $14.71. The 52-week low price of Sage Therapeutic (SAGE) is $4.62.

What is Sage Therapeutic price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Sage Therapeutic (SAGE) is 1.03

What is the Market Cap of Sage Therapeutic?

The market capitalization of Sage Therapeutic (SAGE) is $457.42M

What is Sage Therapeutic’s stock symbol?

The stock symbol (or ticker) of Sage Therapeutic is SAGE

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top